Delayed onset of neuropsychiatric effects associated with montelukast

Irish Journal of Psychological Medicine

Volumn 29, Issue 2, 2012, Pages 125-127

  Byrne, Fintan ^a   Oluwole, Bolarinwa ^b   Whyte, Vanessa ^c   Fahy, Sabina ^d   McGuinness, Delia ^e  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c Castle St Surgery   (Ireland)

^d St Brigids Hospital   (Ireland)

^e CAMHS   (Ireland)

Author keywords

Asthma; Delayed onset adverse effects; Leukotriene receptor antagonist; Montelukast; Neuropsychiatric adverse effects

Indexed keywords

BECLOMETASONE; MONTELUKAST;

ANXIETY; ARTICLE; ASTHMA; CASE REPORT; CAUCASIAN; CHILD; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HUMAN; IRELAND; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PATIENT REFERRAL; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SLEEP WALKING;

EID: 84869414912     PISSN: 07909667     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0790966700017432     Document Type: Article

References (13)

1. Global Strategy for Asthma Management and Prevention 2009 (Update)
2. Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing-information.jsp accessed 17/09/10
3. Canadian Drug Bank available at http://www.drugbank.ca/drugs/DB00471 accessed 17/09/10
4. Cohen S, Taitz J, and Jaffé A. Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline? Arch Dis Child 2007; 92:847-849.
5. Wallerstedt SM et al. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf. 2009 Sept;18(9):858-64
6. Leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). Healthcare Professional Sheet, Washington (DC): US Food and Drug Administration; 2009.
7. Philip G, Hustad C, Noonan G, Malice M-P, Ezekowitz A, Reiss T F, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6
8. Philip G, Hustad CM, Malice M-P, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behaviour-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706
9. Kelsay K. Assessing risk: Data from montelukast clinical trials. J Allergy Clin Immunol 2009;124:697-8
10. Goodwin R, Eaton W. Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore epidemiological catchment area follow-up. Am J Public Health 2005; 95:717-22.
11. McQuaid E, Kopel S, Nassau J. Behavioral adjustment in children with asthma. J Dev Behav Pediatr 2001; 22:430-9.
12. Skillman K, Stumpf J. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011; 31:524.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.